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RESEARCH PAPER
Resorcinol-, catechol- and saligenin-based bronchodilating b2-agonists as
inhibitors of human cholinesterase activity
Anita Bosaka, Anamarija Knezevicb, Ivana Gazic Smilovicb, Goran Sinkoa and Zrinka Kovarika
aInstitute for Medical Research and Occupational Health, Zagreb, Croatia; bRud-er Boskovic Institute, Zagreb, Croatia
ABSTRACT
We investigated the influence of bronchodilating b2-agonists on the activity of human acetylcholinesterase
(AChE) and usual, atypical and fluoride-resistant butyrylcholinesterase (BChE). We determined the inhibition
potency of racemate and enantiomers of fenoterol as a resorcinol derivative, isoetharine and epinephrine
as catechol derivatives and salbutamol and salmeterol as saligenin derivatives. All of the tested compounds
reversibly inhibited cholinesterases with Ki constants ranging from 9.4lM to 6.4mM and had the highest
inhibition potency towards usual BChE, but generally none of the cholinesterases displayed any stereo-
selectivity. Kinetic and docking results revealed that the inhibition potency of the studied compounds
could be related to the size of the hydroxyaminoethyl chain on the benzene ring. The additional p–p
interaction of salmeterol’s benzene ring and Trp286 and hydrogen bond with His447 probably enhanced
inhibition by salmeterol which was singled out as the most potent inhibitor of all the cholinesterases.
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Introduction
The transfer of nervous impulses via acetylcholine (ACh) depends
on a series of well-tuned receptors, enzymes that take part in the
synthesis and hydrolysis of ACh and a series of transporters1. In
chronic inflammatory respiratory diseases (asthma and chronic
obstructive pulmonary disease), ACh levels increase, which leads
to the contraction of the smooth bronchial muscle tissue, intensi-
fied mucous secretion, chronic coughing and immune stimula-
tion2,3. The degradation of ACh in the organism takes place
through the activity of acetylcholinesterase (AChE), which thus ful-
fils its physiological role. This role is shared by the closely related
enzyme butyrylcholinesterase (BChE), an enzyme that does not
possess a known physiological substrate, but does take part in the
bioconversion of several xenobiotics, in the metabolism of lipids
and lipoproteins and serves as a backup enzyme in acetylcholine
hydrolysis when AChE is inhibited4–7. Both AChE and BChE are
crucial in the treatment of neurodegenerative disorders such as
Myasthenia gravis, Alzheimer and Parkinson’s disease, since gener-
ally all drugs in use act by inhibiting AChE and BChE activity6,8.
The activity of both enzymes depends on factors such as ethnicity,
exposure to anticholinergic reagents such as organophosphorus
and carbamate pesticides, nerve agents and anticholinergic
drugs4,9,10. BChE activity is additionally affected by flavonoids or
natural anticholinesterase toxins in food and drugs whose biocon-
version involves the action of BChE, like echothiophate, eye drops
for glaucoma treatment, anti-Alzheimer drugs or the bronchodila-
tor bambuterol4,11–15. However, the efficacy of any drug that tar-
gets BChE activity can be affected by the human BCHE gene
polymorphism. At present, more than 56 mutations of the human
BCHE gene have been identified16, and different catalytic proper-
ties or lower enzyme levels than of usual BChE have been con-
firmed for several BChE variants; for example, individuals
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homozygous for atypical butyrylcholinesterase can experience pro-
longed apnoea if the muscle relaxant succinylcholine or mivacu-
rium are administered16,17.
b-Adrenergic agonists are potent bronchodilators widely used
in the management of bronchial asthma. These agents interact
with b2-adrenergic receptors on the smooth muscle of bronchial
tissue relieving bronchospasms and reducing airway resistance.
Beside the bronchial tissue b-adrenergic agonists also act on other
tissues where signals to other cells are regulated by acetylcholine,
like smooth muscles of the vascular system, intestines and uterus.
Recent studies have shown that oral intake of salbutamol and
ephedrine appeared to be effective supplement treatments in
severe cases of acetylcholine receptor (AChR)18, while chronic
treatment with certain b2-agonists relieved neuropathic pain19.
Also, recent studies demonstrated that some bronchodilators
could be used as additional antidotes in the treatment of poison-
ing by organophosphates, either in accidental poisonings by
organophosphate pesticides or following acts of terrorism using
nerve agents20–23. Organophosphates act through the inhibition of
AChE consequently leading to a collapse of the respiratory system.
The studies of the effects of AChE and BChE inhibition in KO mice
have shown that the respiratory function is more sensitive to anti-
cholinesterases in AChE heterozygotes than in wild-type mice, sug-
gesting that BChE is an important enzyme for the respiratory
function and should be left unaffected by medications that have
the ability to reduce cholinesterase activity24. Ventilatory, inflam-
matory and lethal effects of sarin may be limited by the use of
epinephrine and oxygen20, while the protective activity of salbuta-
mol was demonstrated in diisopropylfluorophosphate (DFP) poi-
soning21,22. Also, treatment with Combivent (a drug consisting of
ipratropium and salbutamol) improved the respiratory outcome
after exposure to soman but did not influence the final lethal
outcome23.
Among the various chiral drugs, one enantiomer is often more
active than another in treating a medical condition. An example is
the (R)-enantiomer of salbutamol, which is approximately 80 times
more potent as a b-adrenoceptor agonist than (S)-enantiomer and
the administration of pure (R)-salbutamol improved therapeutic
activity and reduced side effects25. Similar in vivo results were
obtained with enantiomers of terbutaline26. AChE and BChE are
stereoselective enzymes in the interaction with various
esters7,9,27,28. In interaction with bambuterol, which in its racemic
form is in use as a prodrug of terbutaline, both enzymes prefer
(R)- over (S)-bambuterol7,27,28.
In our previous studies, we demonstrated that some derivatives
of resorcinol were reversible inhibitors of human cholinester-
ases9,28,29. In this study, we extended our research on other b-ago-
nists with a resorcinol-, catechol- and saligenin-containing
structure. Here, we determined the inhibition potency of fenoterol
as a resorcinol derivative, isoetharine and epinephrine as catechol
derivatives, and salbutamol and salmeterol as saligenin derivatives
(Figure 1) towards human AChE and three variants of human BChE
(usual, atypical and fluoride resistant). The systematic structural dif-
ferences between compounds and their inhibition potency towards
certain cholinesterases were analysed by molecular modelling.
Material and methods
Chemicals
Racemic epinephrine, isoetharine, fenoterol and terbutaline, as
well as (R)-epinephrine, were purchased (Sigma-Aldrich, St. Louis,
MO) in the form of salts and converted to hydrochloride salts
Figure 1. The chemical structure of the studied resorcinol, catechol and saligenin derivatives. Asterisk denotes a chiral carbon atom.
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(detailed in Supplementary material). All of the chemicals, reagents
and solvents for the preparation of resorcinol, catechol and salige-
nin derivatives were purchased from commercial sources and used
without further purification. Acetylthiocholine iodide (ATCh), pro-
pionylthiocholine iodide (PTCh) and 5,50-dithiobis(2-nitrobenzoic
acid) (DTNB) were purchased from Sigma-Aldrich. All of the inhibi-
tors and substrates were dissolved in water, while DTNB was dis-
solved in 0.1 M sodium phosphate buffer (pH 7.4). Only salmeterol
was dissolved in ethanol due to its low solubility, while all further
dilutions were made in water.
Enzymes
Human native serum was used as a source of BChE. Recombinant
human AChE was a gift from Dr Florian Nachon (Departement de
Toxicologie, IRBA, France). BChE variants were confirmed earlier as
described previously30,31. The usual BChE was collected from a
female donor at the Institute for Medical Research and Occupational
Health, Zagreb, Croatia (IMROH); the atypical BChE was a gift from
Dr Oksana Lockridge (University of Nebraska Medical Centre, Eppley
Institute, Omaha, NE), and specimens of the fluoride resistant BChE
were a gift by Dr Robert T. Evans (Cholinesterase Investigation Unit,
St’ James University Hospital, Leeds, Great Britain). Enzyme dilutions
were done in phosphate buffer and those of recombinant AChE
with the addition of 0.01% BSA. This study was reviewed and
approved by the Ethics Committee of IMROH.
Synthesis
Racemic salbutamol and salmeterol were synthesised starting from
methyl 5-acetylsalicylate (Sigma-Aldrich) according to literature
procedures described previously32,33.
The enantiomers of salbutamol and (R)-terbutaline were
prepared from their racemic form using diastereomeric salt crystal-
lization method32,34. The resolving agent for (R)-terbutaline and
(R)-salbutamol precursor was (þ)-O,O0-di-p-toluoyl-D-tartaric acid
and ()-O,O0-di-p-toluoyl-L-tartaric acid for a precursor for (S)-sal-
butamol. Enantiomeric excess (ee) for the obtained enantiomers
was determined using a brush-type chiral stationary phase previ-
ously synthesised in our laboratory (CSP 1)35. The obtained
ee were 99%, 96% and 92% for (S)-salbutamol, (R)-terbutaline and
(R)-salbutamol, respectively.
Enantiomers of fenoterol and salmeterol were resolved using
semipreparative chiral chromatography. The columns used were
CHIRALLICA PST-4 (AD-type column; Chirallica d.o.o., Croatia) and
CHIRALLICA PST-2 (OJ-type column; Chirallica d.o.o., Croatia) for
fenoterol and salmeterol, respectively. The obtained ee were 98%,
96%, 97% and 86% for (S,S)-fenoterol, (R,R)-fenoterol, (R)-salmeterol
and (S)-salmeterol, respectively. The absolute configuration of
enantiomers was determined by comparison of the elution order
of these compounds on AD and OJ columns with literature
data36,37 (detailed in Supplementary).
Reversible inhibition
Enzyme activities were measured in 0.1 M phosphate buffer, pH
7.4 at 25 C, on CARY 300 spectrophotometer equipped with tem-
perature controller (Varian Inc., Australia) by Ellman method at
412 nm38. ATCh was used as a substrate for AChE and PTCh as a
substrate for BChE. The reaction mixture contained DTNB (final
concentration 0.3mM), buffer, enzyme suspension, inhibitor
(0.5–10mM) and ATCh or PTCh (0.025–1.0mM). Inhibition of
enzymes was determined by measuring the decrease in enzyme
activity in the presence of inhibitors. The baseline activity was
determined in the presence of water since the proportion of etha-
nol in AChE and BChE activity measurement was up to 0.08% and
0.16%, respectively, which does not affect the enzyme activity.
The dissociation constant for an enzyme–inhibitor complex
K(I) was evaluated from the impact of substrate concentrations
[S] on the degree of inhibition applying the Hunter–Downs
Figure 2. Reversible inhibition of human AChE and three BChE variants (usual,
atypical and fluoride resistant) by racemic salmeterol. Points indicate the average
apparent enzyme-inhibitor constant Ki,app (±SE) determined at a given substrate
concentration (S) according to the Hunter–Downs equation. The lines are the
result of linear regression analysis where the y-intercept represents the enzyme-
inhibitor dissociation constant, K(I).
Table 1. Reversible inhibition of human AChE and three BChE variants (usual, atypical and fluoride resistant) by bron-
chodilating b2-agonists.
K(I)/mM
AChE usual BChE atypical BChE fluoride-resistant BChE
Resorcinol derivatives
Metaproterenolb 3.1 ± 1.2 0.55 ± 0.11 6.1 ± 0.7 0.87 ± 0.18
Terbutaline 4.8 ± 0.2 0.18 ± 0.15a 3.3 ± 0.7a 0.30 ± 0.32a
Fenoterol 0.86 ± 0.05 0.024 ± 0.001 0.63 ± 0.03 0.061 ± 0.017
Catechol derivatives
Epinephrine 6.4 ± 1.1 3.7 ± 1.2 1.6 ± 1.0 3.8 ± 1.5
Isoproterenolb 2.5 ± 1.0 0.47 ± 0.21 1.6 ± 0.3 0.99 ± 0.12
Isoetharine 0.21 ± 0.04 0.031 ± 0.003 0.26 ± 0.05 0.086 ± 0.004
Saligenin derivatives
Salbutamol 2.0 ± 0.2 0.071 ± 0.006 1.4 ± 0.2 0.19 ± 0.02
Salmeterol 0.030 ± 0.002 0.013 ± 0.001 0.086 ± 0.018 0.0098 ± 0.0023
The enzyme-inhibitor complex dissociation constant (K(I)± SE) was determined by linear regression from Ki,app constants
obtained from at least two experiments.
aReference29.
bReference9.
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equation17,39:
Ki;app ¼ viv0  vi  I½  ¼ K Ið Þ þ
K Ið Þ
K Sð Þ
 S½ 
where Ki,app is an apparent enzyme-reversible inhibitor complex
dissociation constant obtained at a given substrate concentration
[S] in the presence of inhibitor concentration [I] and calculated
from the enzyme activities v0 and vi measured without inhibitor
and in the presence of inhibitor concentration [I], respectively15.
K(I) is the enzyme-reversible inhibitor complex dissociation con-
stant and can stand for a complex formed at the catalytic site or
for a complex formed at the peripheral site of the enzyme. K(S) is
the enzyme-substrate dissociation constant that could be approxi-
mated to the Michaelis constant or to the enzyme-substrate dis-
sociation constant when two molecules of the substrate are
bound to the enzyme.
Molecular modelling
The docking of the studied compounds was performed using the
Accelrys DiscoveryStudio 2.1 CDOCKER docking protocol and
CHARMm force field. For the structural model of AChE, we used a
crystal structure deposited in the Protein Data Bank, PDB ID
1B4140 and PDB ID 2PM8 as a model for usual BChE41. Models for
atypical and fluoride-resistant BChE were constructed using the
2PM8 structure as a model in which Asp70 was replaced with Gly
as a model for atypical BChE, and Thr243 with Met or Gly390 with
Val as models of fluoride-resistant BChE. All of the constructed
models were minimised using the CHARMm force field according
to the docking protocol described previously9,42. As a result of
molecular docking, a set of 20 possible poses per one compound
and enzyme pair was analysed and the pose with the highest
CDOCKER interaction energy was selected for further analysis.
Results and discussion
The tested bronchodilating b2-agonists were divided into three
groups according to the disposition of their hydroxyl groups on
the benzene ring, resembling the structural feature of resorcinol,
catechol and saligenin (Figure 1). The hydroxyl groups at the ben-
zene were in the meta position in the resorcinol group, and in the
ortho position in the catechol group. In the saligenin group, the
hydroxyl group and the hydroxymethyl group were in the ortho
position. Derivatives of each group differed in the size of the
hydroxyaminoethyl chain attached to the benzene ring.
Inhibition of human AChE
Kinetic studies revealed that all of the studied bronchodilating
b2-agonists reversibly inhibited AChE (Figure 2, an example of
Table 2. The highest CDOCKER interaction energy (CIE) between 20 poses per
one bronchodilating b2-agonists cholinesterase pair.
—CIE (kJ/mol)
AChE usual BChE atypical BChE
Resorcinol derivatives
Metaproterenol 178 149 178
Terbutaline 170 168 142
Fenoterol 245 182 231
Catechol derivatives
Epinephrine 169 146 190
Isoproterenol 186 181 138
Isoetharine 203 212 204
Saligenin derivatives
Salbutamol 178 169 156
Salmeterol 323 285 267
Table 3. List of bronchodilating b2-agonists cholinesterase interactions.
AChE Usual BChE Atypical BChE
Resorcinol derivatives
Metaproterenol H-bond: Asp74, Tyr124, Ser125, Glu202,
Ser203
H-bond: Asp70, Trp82, Glu197 H-bond: Gly115, Tyr128, Glu197, Ser198,
His438
p–p: Trp86 p–p: Trp82 p–cation: Trp82
Terbutaline H-bond: Asp74, Gly82, Tyr124, Tyr337,
Tyr341
H-bond: Glu197, His438 H-bond: Glu197, Leu286
p–p: Trp86 p–cation: Trp82
p–cation: Tyr341 p–alkyl: Ala328
Fenoterol H-bond: Asp74, Tyr124, Ser125, Tyr337,
Tyr341,
H-bond: Asp70, Tyr128, Glu197, His438 H-bond: Thr120, Tyr128, Glu197, Tyr332,
His438
p–p: Trp86, Trp286, Tyr341 p–cation: Trp82
p–alkyl: Ala328
p–cation: Trp82, His438
p–alkyl: Ala328
Catechol derivatives
Epinephrine H-bond: Asp74, Gly122, Tyr124, Ser125,
Glu202, Ser203, Tyr337, Tyr341
H-bond: Glu197, His438, Gly439 H-bond: Trp82, Gly121, Tyr128, Glu197,
Ser198, His438
p–p: Trp86 p–p: Trp82 p–p: His438
p–r: Gly116
Isoproterenol H-bond: Asp74, Tyr124, Phe295, Tyr337,
Tyr341,
H-bond: Asp70, Ser79, Glu197, Tyr332,
His438
H-bond: Tyr440
p–p: Trp286, Tyr341 p–cation: Trp82, His438 p–p: Trp82
p–alkyl: Ala328
Isoetharine H-bond: Tyr124, Tyr133, Glu202, Tyr337 H-bond: Glu197, Ser198, Leu286, His438 H-bond: Thr120, Glu197, Ser198, His438
p–p: Trp86 p–p: His438 p–p: His438, Gly116, Gly117
p–alkyl: Tyr124, Phe297 p–alkyl: Trp82 p–alkyl: Trp82
Saligenin derivatives
Salbutamol H-bond: Asp74, Gly121, Tyr124, Tyr337 H-bond: Asp70, Asn83, His438 H-bond: Trp82, Gly121
p–p: Trp86, Trp337 p–cation: Trp82 p–p: Trp82
p–cation: Tyr341 p–r: Gly116
Salmeterol H-bond: Asp74, Tyr124, Phe295, Arg296,
Tyr337, Tyr341, His447
H-bond: Trp82, Thr122, Tyr128, Glu197,
His438
H-bond: Trp82, Thr120, Gly121, Glu197
p–p: Trp86, Trp286 p–p: Trp82 p–p: Trp82, His438
p–cation: His438
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inhibition by racemic salmeterol), with enzyme-inhibitor dissoci-
ation constants (K(I)) ranging between 30 lM and 6.4mM (Table 1),
classifying these compounds as low-potency inhibitors29,43.
Ranges of K(I) constants of resorcinol, catechol and saligenin
derivatives were very similar, indicating that the inhibition potency
of the tested bronchodilating b2 agonists towards human AChE
does not depend on the disposition of hydroxyl groups on the
benzene ring. However, it seems that the inhibition potency of the
tested b2-agonists depends on the size of the hydroxyaminoethyl
chain attached to the benzene ring. For example, in the resorcinol
group, metaproterenol and terbutaline differ only in the end of
hydroxyaminoethyl chain (isopropyl in metaproterenol versus tert-
butyl in terbutaline) exhibiting very similar inhibition, while the
enlargement of the hydroxyaminoethyl chain with the hydroxy-
benzyl group, as it is a fenoterol, caused a fivefold increase in
inhibition potency. In the catechol group, an elongation of the
hydroxyaminoethyl chain from methyl to isopropyl lead to a 2-fold
increase in inhibition potency of isoproterenol compared to
epinephrine. Additional substitution on the hydroxyaminoethyl
chain with the ethyl group, as in isoetharine, caused a further 12-
fold higher inhibition potency compared to isoproterenol. The
largest, 67-fold, increase in inhibition potency was observed in the
saligenin group between salbutamol and salmeterol, where the
largest difference in the size of hydroxyaminoethyl chain was.
Additionally, when compounds with identic hydroxyaminoethyl
chain but different disposition of hydroxyl group on benzene ring
(metaproterenol vs. isoproterenol) were compared, no difference
in inhibition potency was observed. Similarly two times higher
inhibition potency of salbutamol, compared to terbutaline, can be
attributed to the substitution of one hydroxyl group on benzene
ring with the hydroxymethyl group. From all of the tested bron-
chodilating b2-agonists, salmeterol was singled out as the most
potent inhibitor with an inhibition potency similar to that of flavo-
noids quercetin and myricetin44.
The inhibition potency correlated well with the docking results
expressed here as the interaction energy of the bronchodilating
Figure 3. Computational molecular modelling of b2-agonists and human AChE (PDB ID 1B41). Stereo view of salmeterol (A) and terbutalin (B) in the active site of
AChE. Ligands create H-bonds with residues (green-dashed lines). Hydrophobic p–p interactions with aromatic residues are represented as cyan-dashed lines and
p–cation interactions are represented as orange-dashed lines. The hydrogen atoms of the residues have been omitted for better visibility.
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b2-agonistsAChE complex (Table 2). The highest interaction
energy was that of salmeterol, the most potent AChE inhibitor.
All of the predicted non-covalent interactions of bronchodilating
b2-agonists with amino acid residues defining the AChE active site
gorge are summarised in Table 3. The analysis of these
interactions showed that, regardless of the size of the hydroxyami-
noethyl chain on the benzene ring, the chain was always directed
to the peripheral site of the active centre gorge of the enzyme.
This orientation was due to the formation of hydrogen bonds with
Tyr124 and Asp74 (Figure 3(A,B)). These interactions, together with
Figure 4. Computational molecular modelling of b2-agonists and human BChE (PDB ID 2PM8). Stereo view of salmeterol (A), isoetharine (B) and fenoterol (C) in the
active site of usual BChE. Ligands create H bonds with residues (green dashed lines). Hydrophobic p–p interactions with aromatic residues are represented as cyan-
dashed lines and p–cation interactions are represented as orange-dashed lines. The hydrogen atoms of the residues have been omitted for better visibility.
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interactions with tyrosines 337 and 341 and the position of the
benzene ring relative to Trp86, were those that governed the posi-
tioning of the tested compounds into the active site of AChE. It
seems that epinephrine was the weakest inhibitor of AChE merely
because of the lack of stabilisation by hydrogen bonds with tyro-
sine residues 337 and 341. The difference between the inhibition
potency of particular b2-agonists of the resorcinol, catechol and
saligenin groups, was attributable to additional hydrogen bonds
and hydrophobic interactions between the hydroxyaminoethyl
chain and residues (Table 3). Salmeterol’s high inhibition potency
could have been due to the additional p–p interaction of sal-
meterol’s benzene ring and Trp286 and hydrogen bond with
His447 (Figure 3(A)).
Inhibition of human BChE variants
The studied bronchodilating b2-agonists reversibly inhibited all
BChE variants (Figure 2, an example of inhibition by racemic sal-
meterol), with K(I) constants ranging between 9.8lM and 3.8mM
(Table 1). Generally, atypical and fluoride-resistant variants were
up to 26 and 2.8 times, respectively, more weakly inhibited than
usual BChE. The fluoride-resistant BChE has been characterised by
an amino acid substitution changing T243M and G390V that are
far from the enzyme-active centre but could cause conformational
changes resulting in a lower inhibition potency of positively
charged ligands45. The decrease of inhibition potency towards
atypical BChE compared to usual BChE could be a consequence of
the natural mutation of aspartate 70 to glycine (D70G), a residue
located in the peripheral site of the active centre of BChE and
close to the entrance of the active centre gorge. The inhibition
potency of fenoterol, isoetharine and salmeterol towards usual
BChE was up to 23, 120 and 5.5 times higher, respectively, than
the potency of other resorcinol-, catechol- and saligenin-based
compounds. The same trend of inhibition potency was observed
for atypical and fluoride-resistant variants (Table 1). This indicates
a positive correlation between the size of the hydroxyaminoethyl
chain and the inhibition potency toward the BChE variants, simi-
larly to our observation for AChE inhibition. Out of the eight bron-
chodilating b2-agonists tested, salmeterol was the most potent
inhibitor of all BChE variants with a constant similar to that for
donepezil, a drug used to treat Alzheimer’s disease45. The kinetic
results correlated well with the docking results (Table 2); the
higher the inhibitory potency of the compound, the higher the
CDOCKER interaction energy. It seems that the inhibition potency
of compounds with resorcinol-, catechol- or saligenin-based com-
pounds towards usual BChE was primarily a consequence of cati-
on–p interaction involving Trp82 (Table 3) that enabled their
position and orientation in the active site of BChE allowing add-
itional interactions such as hydrogen bonds with Glu197 and
His438 residues (Figure 4(A–C)). The highest inhibition potency of
salmeterol could be attributed to the additional p–p interaction
with Trp82, which anchored the saligenin part deeper in the active
site and directed the hydrocarbon chain towards the exit of the
active site of the usual BChE. This position seemed optimal for the
inhibition of BChE.
Inhibition selectivity
Due to a difference in residues lining the active site of AChE
and BChE, these two enzymes have different reactivity toward sub-
strates, inhibitors and ligands9,10,44,46. Therefore, it is important to
evaluate the selectivity of compounds that either targets the activ-
ity of AChE, as it is with some drugs for treating neurodegenera-
tive disorders like Alzheimer’s disease46 or prodrugs whose
bioconversion includes the action of BChE, as in the case of bam-
buterol9,11. The selectivity of the studied bronchodilating b2-ago-
nists was determined from the ratio of the corresponding K(I)
constants for AChE and BChE. Generally, all of the compounds
were more potent inhibitors of BChE than of AChE. The most
selective inhibitor was fenoterol, followed by salbutamol and ter-
butaline that inhibit usual BChE 36, 28 and 27 times more potently
than AChE, respectively. It is worthy to mention that these b2-ago-
nists are currently the most frequently used bronchodilators.
Catechol derivatives were the least selective inhibitors, out of
which epinephrine showed the lowest selectivity. Salmeterol, the
most potent inhibitor of all of the tested cholinesterases, displayed
only a two times higher potency towards BChE than toward AChE.
In view of the BChE polymorphism, inhibition of fluoride-resistant
BChE is similarly selective as that of usual BChE, while no selectiv-
ity in the inhibition of the atypical variant was determined.
Stereoselectivity of human AChE and usual, atypical and
fluoride-resistant BChE
The tested compounds are chiral molecules (Figure 1) and the
stereoselectivity of cholinesterases could have been expected as a
result of a difference in the binding of enantiomers. The
Table 4. Reversible inhibition of human AChE and three BChE variants (usual, atypical and fluoride-resistant) by enantiomers of bron-
chodilating b2-agonists.
K(I)/mM
AChE Usual BChE Atypical BChE Fluoride-resistant BChE
Resorcinol derivatives
(R)-terbutaline 2.0 ± 0.3 0.11 ± 0.03 1.0 ± 0.1 0.22 ± 0.05
(R,R)-fenoterol 0.54 ± 0.03 0.0094 ± 0.0008 0.13 ± 0.02 0.019 ± 0.004
(S,S)-fenoterol 0.35 ± 0.03 0.013 ± 0.001 0.10 ± 0.00 0.037 ± 0.005
Catechol derivatives
(R)-epinephrine 3.2 ± 0.4 4.7 ± 1.8 12 ± 2 —
(R)-isoproterenol 2.0 ± 0.5 0.81 ± 0.13 1.4 ± 0.1 1.4 ± 0.2
Saligenin derivatives
(R)-salbutamol 4.0 ± 0.3 0.19 ± 0.04 2.3 ± 0.2 0.30 ± 0.06
(S)-salbutamol 1.8 ± 0.1 0.31 ± 0.05 1.5 ± 0.2 0.30 ± 0.04
(R)-salmeterol 0.033 ± 0.003 0.015 ± 0.001 0.071 ± 0.019 0.031 ± 0.004
(S)-salmeterol 0.028 ± 0.006 0.015 ± 0.001 0.067 ± 0.013 0.020 ± 0.003
— not measured.
Enzyme-inhibitor complex dissociation constants (K(I)±SE) were determined by linear regression from Ki,app constants obtained from at
least two experiments.
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stereoselectivity was determined from the ratio of K(I) constants
determined for the (R) and (S) enantiomers of fenoterol, salbuta-
mol and salmeterol (Table 4). For terbutaline, epinephrine and iso-
proterenol, stereoselectivity was estimated by comparing the K(I)
constants obtained for racemate with those for the (R) enantiomer
(Table 4). Irrespectively of whether stereoselectivity was deter-
mined or just estimated, for most of the compounds, neither AChE
nor BChEs displayed any stereoselectivity; the exception was AChE
and atypical BChE preferring 2- and 3-fold (R)-terbutaline over its
racemate, respectively. The lack of cholinesterase stereoselectivity
was probably the consequence of interactions with residues that
did not involve the chiral centre of the tested compounds. Indeed,
the molecular modelling of complexes demonstrated that the sta-
bilisation of the compounds into the active site of the enzymes
was based on other interactions (Figures 3 and 4).
Conclusions
Due to the important and versatile functions of cholinesterases in
organisms, it is important to define the inhibition potency of com-
pounds that reduce the level of their hydrolytic activity, especially
for those in use as drugs. All of the tested b2-agonists are in use
as bronchodilators, except isoetharine whose use was discontin-
ued. Our results have shown that the compounds are reversible
cholinesterase inhibitors that reduce human cholinesterase
activity and therefore can affect their roles in an organism.
Cholinesterases had the lowest affinity towards epinephrine, the
hormone of adrenal glands and neurons that plays an important
role in the organism during acute stress response. Interestingly,
AChE also displayed low affinity towards terbutaline and salbuta-
mol, compounds that are active components of the most com-
monly used bronchodilators. It should also be mentioned that the
tested b2-agonists showed the highest inhibition potency towards
usual BChE among the three variants of BChE. Moreover, our
results show that the racemates of these compounds in terms of
cholinesterase inhibition are safe for use since there was no
stereoselectivity exhibited in the interaction with cholinesterases.
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